TrevogrumabUnderstand the science
What blocking two muscle signals changed in an early human trial
2 numbered sourcesSource years 2024–2026
A peptide is a short amino-acid chain linked by peptide bonds. Larger proteins also use amino-acid chains, sometimes arranged to bind a very specific target. Trevogrumab is an investigational monoclonal antibody against myostatin, also known as GDF8. An older phase 1 trial investigated the effects of blocking myostatin and a second signal called activin A, separately and together. [1]
The trial had two parts. Its single-exposure portion included healthy postmenopausal women and compared groups receiving one antibody, both antibodies or placebo. A second portion studied repeated exposure in additional groups. Garetosmab was the antibody directed against activin A. Using separate groups allowed investigators to ask whether the response to blocking both signals resembled the response to blocking each individually. [1]
The primary measures involved treatment-emergent adverse events. The investigators also used MRI to assess thigh muscle volume and DXA to measure body composition. They reported greater muscle growth in the groups receiving both antibodies than with either alone in the relevant comparisons. Changes in fat measurements were also observed. The number of people and length of follow-up were appropriate to an early study of specified exposures and do not resolve longer-term clinical questions. [1]
This was a study of two antibodies in defined groups, including healthy postmenopausal women. It did not test a weight-management regimen with semaglutide. Later studies that included semaglutide address a different setting and include a separate comparator. The phase 1 study helps identify which signals can influence the tissue measurements. It supplies no outcome estimate for people in other populations or for the use of the antibodies to treat a specific disease. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 2.Regeneron Pharmaceuticals, Inc. A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity. ClinicalTrials.gov (publication 2024-03-07, record updated 2026-09-01). (opens in a new tab)
clinicaltrials.gov↩ Back to text
